30077712|t|Stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic pharmacodynamics, and toxic properties of vasicine enantiomers in vitro and in vivo.
30077712|a|Vasicine (VAS) is a potential natural cholinesterase inhibitor for treatment of Alzheimer's disease. Due to one chiral centre (C-3) presenting in molecule, VAS has two enantiomers, d-vasicine (d-VAS) and l-vasicine (l-VAS). The study was undertaken to investigate the stereoselective glucuronidation metabolism, pharmacokinetics, anti-amnesic effect and acute toxicity of VAS enantiomers. In results, the glucuronidation metabolic rate of l-VAS was faster than d-VAS in human liver microsomes and isoenzymes tests, and it was proved that the UDP-glucuronosyltransferase (UGT) 1A9 and UGT2B15 were the major metabolic enzymes for glucuronidation of l-VAS, while only UGT1A9 for d-VAS, which take responsibility of the significantly less metabolic affinity of d-VAS than l-VAS in HLM and rhUGT1A9. The plasma exposure of d-VAS in rats was 1.3-fold and 1.6-fold higher than that of l-VAS after intravenous and oral administration of d-VAS and l-VAS, respectively. And the plasma exposure of the major glucuronidation metabolite d-VASG was one of tenth of l-VASG or more less, no matter by intravenous or oral administration. Both d-VAS and l-VAS were exhibited promising acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities, and the BChE inhibitory activity of d-VAS with IC50 of 0.03 +- 0.001 muM was significantly stronger than that of l-VAS with IC50 of 0.98 +- 0.19 muM. The molecular docking results indicated that d-VAS and l-VAS could bind to the catalytic active site (CAS position) either of human AChE and BChE, and the BChE combing ability of d-VAS (the score of GBI/WAS dG -7.398) was stronger than that of l-VAS (the score of GBI/WAS dG -7.135). Both d-VAS and l-VAS could improving the learning and memory on scopolamine-induced memory deficits in mice. The content of acetylcholine (ACh) after oral administration d-VAS increased more than that of l-VAS in mice cortex, through inhibiting cholinesterase (ChE) and increasing choline acetyltransferase (ChAT). In addition, the LD50 value of d-VAS (282.51 mg kg-1) was slight lower than l-VAS (319.75 mg kg-1). These results indicated that VAS enantiomers displayed significantly stereoselective metabolic, pharmacokinetics, anti-amnesic effect and toxic properties in vitro and in vivo. The d-VAS might be the dominant configuration for treating Alzheimer's disease.
30077712	67	74	amnesic	Disease	MESH:D000647
30077712	117	125	vasicine	Chemical	MESH:C019592
30077712	160	168	Vasicine	Chemical	MESH:C019592
30077712	170	173	VAS	Chemical	MESH:C019592
30077712	198	212	cholinesterase	Gene	590
30077712	240	259	Alzheimer's disease	Disease	MESH:D000544
30077712	316	319	VAS	Chemical	MESH:C019592
30077712	341	351	d-vasicine	Chemical	-
30077712	353	358	d-VAS	Chemical	-
30077712	364	374	l-vasicine	Chemical	MESH:C019592
30077712	376	381	l-VAS	Chemical	MESH:C019592
30077712	495	502	amnesic	Disease	MESH:D000647
30077712	520	528	toxicity	Disease	MESH:D064420
30077712	532	535	VAS	Chemical	MESH:C019592
30077712	599	604	l-VAS	Chemical	MESH:C019592
30077712	621	626	d-VAS	Chemical	-
30077712	630	635	human	Species	9606
30077712	702	739	UDP-glucuronosyltransferase (UGT) 1A9	Gene	54600
30077712	744	751	UGT2B15	Gene	7366
30077712	808	813	l-VAS	Chemical	MESH:C019592
30077712	826	832	UGT1A9	Gene	54600
30077712	837	842	d-VAS	Chemical	-
30077712	918	923	d-VAS	Chemical	-
30077712	929	934	l-VAS	Chemical	MESH:C019592
30077712	938	941	HLM	CellLine	CVCL:X699
30077712	979	984	d-VAS	Chemical	-
30077712	988	992	rats	Species	10116
30077712	1039	1044	l-VAS	Chemical	MESH:C019592
30077712	1090	1095	d-VAS	Chemical	-
30077712	1100	1105	l-VAS	Chemical	MESH:C019592
30077712	1185	1191	d-VASG	Chemical	-
30077712	1212	1218	l-VASG	Chemical	-
30077712	1287	1292	d-VAS	Chemical	-
30077712	1297	1302	l-VAS	Chemical	MESH:C019592
30077712	1328	1348	acetylcholinesterase	Gene	43
30077712	1350	1354	AChE	Gene	43
30077712	1360	1381	butyrylcholinesterase	Gene	590
30077712	1383	1387	BChE	Gene	590
30077712	1420	1424	BChE	Gene	590
30077712	1448	1453	d-VAS	Chemical	-
30077712	1525	1530	l-VAS	Chemical	MESH:C019592
30077712	1607	1612	d-VAS	Chemical	-
30077712	1617	1622	l-VAS	Chemical	MESH:C019592
30077712	1688	1693	human	Species	9606
30077712	1694	1698	AChE	Gene	43
30077712	1703	1707	BChE	Gene	590
30077712	1717	1721	BChE	Gene	590
30077712	1741	1746	d-VAS	Chemical	-
30077712	1806	1811	l-VAS	Chemical	MESH:C019592
30077712	1851	1856	d-VAS	Chemical	-
30077712	1861	1866	l-VAS	Chemical	MESH:C019592
30077712	1910	1921	scopolamine	Chemical	MESH:D012601
30077712	1930	1945	memory deficits	Disease	MESH:D008569
30077712	1949	1953	mice	Species	10090
30077712	1970	1983	acetylcholine	Chemical	MESH:D000109
30077712	1985	1988	ACh	Chemical	MESH:D000109
30077712	2016	2021	d-VAS	Chemical	-
30077712	2050	2055	l-VAS	Chemical	MESH:C019592
30077712	2059	2063	mice	Species	10090
30077712	2091	2105	cholinesterase	Gene	590
30077712	2107	2110	ChE	Gene	590
30077712	2127	2152	choline acetyltransferase	Gene	1103
30077712	2154	2158	ChAT	Gene	1103
30077712	2192	2197	d-VAS	Chemical	-
30077712	2237	2242	l-VAS	Chemical	MESH:C019592
30077712	2290	2293	VAS	Chemical	MESH:C019592
30077712	2380	2387	amnesic	Disease	MESH:D000647
30077712	2442	2447	d-VAS	Chemical	-
30077712	2497	2516	Alzheimer's disease	Disease	MESH:D000544
30077712	Negative_Correlation	MESH:C019592	MESH:D000544
30077712	Negative_Correlation	MESH:C019592	MESH:D000647
30077712	Negative_Correlation	MESH:C019592	590
30077712	Association	MESH:C019592	7366
30077712	Positive_Correlation	MESH:D012601	MESH:D008569
30077712	Negative_Correlation	MESH:C019592	MESH:D008569
30077712	Negative_Correlation	MESH:C019592	43
30077712	Association	MESH:C019592	54600

